Key Highlights
- Seres Therapeutics pivoted to a Q2 net profit of $4.6 million from a prior $19.9 million deficit.
- The swing was primarily fueled by a $25 million gain tied to VOWST and reduced overhead.
- SER-155 early data revealed an 80% clinical response rate without immunosuppressives by day 15.
- Liquid assets and pending Nestlé payments are projected to sustain the runway into March 1, 2027.
Seres Therapeutics, Inc. (NASDAQ: MCRB) pivoted to a Q2 net profit of $4.6 million from a prior $19.9 million deficit, primarily fueled by a $25 million gain tied to VOWST and reduced overhead.
What Happened
Notably, SER-155 early data revealed an 80% clinical response rate without immunosuppressives by day 15, with Liquid assets and pending Nestlé payments projected to sustain the runway into March 1, 2027.
Market Reaction
The disclosed information does not include stock price or trading data for Seres Therapeutics following the Q2 results.
Outlook
Continued follow-up on SER-155's early clinical response data, alongside the timing of pending Nestlé payments supporting the runway into March 1, 2027, represent the next relevant developments for Seres Therapeutics.
FAQs
Q: How did Seres Therapeutics' Q2 results change year-over-year?
A: The company swung to a net profit of $4.6 million, from a prior $19.9 million deficit, primarily due to a $25 million gain tied to VOWST.
Q: What did SER-155 early data show?
A: An 80% clinical response rate without immunosuppressives by day 15.
Q: How long is Seres Therapeutics' cash runway expected to last?
A: Into March 1, 2027, supported by liquid assets and pending Nestlé payments.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.